Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - CuraGen Corporation (NasdaqNM:CRGN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Reports
555 Long Wharf Drive, 11th Floor
New Haven, CT 06511
Phone: (203) 401-3330
Fax: (203) 401-3331
Employees (last reported count): 358
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

·Insider and 5%+ Owners: 34%
·Over the last 6 months:
 · 4 insider sells; 871.0K shares
  (5.0% of insider shares)
·Institutional: 59% (89% of float)
(192 institutions)
·Net Inst. Buying: 1.30M shares (+4.32%)
(prior quarter to latest quarter)
More From Market Guide
 ·Ratio Comparisons
Business Summary
CuraGen Corporation is a genomics-based biopharmaceutical company. The Company researches, develops and uses technologies based on the discovery of genes, as well as the Company's understanding of their functions and relationships, to accelerate the discovery and development of products to improve human and animal health and the vitality of agriculture, in collaboration with other companies and through the Company's proprietary internal programs. The Company's genomics technologies and information systems are comprised of four primary components: SeqCalling, GeneCalling, PathCalling and SNPCalling. The Company may also provide certain support services necessary to characterize gene and target discoveries, subscriptions to its databases and integration with a collaborator's existing development pipeline of products. The Company uses its GeneScape software platform in such collaborations to manage its processes and provide access to the Company's databases.
More from Market Guide: Expanded Business Description

Financial Summary
CRGN is a genomics based biopharmaceutical company that is advancing the discovery and development of pharmaceutical and life science products through the systematic application of genomics. For the six months ended 6/30/01, revenues rose 12% to $11.9 million. Net loss rose 38% to $15.6 million. Results reflect increased amounts earned under collaborative R&D agreements, offset by increased research and development and personnel expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation

Jonathan Rothberg, Ph.D., 37
Chairman, Pres, CEO
David Wurzer, 42
Exec. VP, Treasurer and CFO
Christopher McLeod, 45
Exec. VP
Hovan Asdourian, 51
Sr. VP, Bus. Devel.
Michael McKenna, Ph.D., 38
VP- Operations
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CRGNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
Recent Price$20.39 
52-Week High
on 31-Oct-2000
Daily Volume (3-month avg)587.8K
Daily Volume (10-day avg)744.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-54.8%
52-Week Change
relative to S&P500
Share-Related Items
Market Capitalization$991.6M
Shares Outstanding48.6M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 31-Mar-2000
Per-Share Data
Book Value (mrq)$7.86 
Earnings (ttm)-$0.73 
Earnings (mrq)-$0.21 
Sales (ttm)$0.51 
Cash (mrq)$11.14 
Valuation Ratios
Price/Book (mrq)2.59 
Price/Sales (ttm)39.87 
Income Statements
Sales (ttm)$22.2M
EBITDA (ttm)-$40.5M
Income available to common (ttm)-$31.3M
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-7.39%
Return on Equity (ttm)-12.44%
Financial Strength
Current Ratio (mrq)35.72 
Debt/Equity (mrq)0.41 
Total Cash (mrq)$541.9M
Short Interest
As of 8-Aug-2001
Shares Short1.17M
Percent of Float3.6%
Shares Short
(Prior Month)
Short Ratio1.90 
Daily Volume615.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.

Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.